| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | EX-527 | GDSC1000 | pan-cancer | AAC | 0.0038 | 0.9 |
| mRNA | BRD-K33199242 | CTRPv2 | pan-cancer | AAC | -0.0041 | 0.9 |
| mRNA | BRD-K27224038 | CTRPv2 | pan-cancer | AAC | 0.0085 | 0.9 |
| mRNA | Bexarotene | GDSC1000 | pan-cancer | AAC | -0.0038 | 0.9 |
| mRNA | KH-CB19 | CTRPv2 | pan-cancer | AAC | 0.0049 | 0.9 |
| mRNA | BRD-A05715709 | CTRPv2 | pan-cancer | AAC | 0.006 | 0.9 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0036 | 0.9 |
| mRNA | AZD6244 | CTRPv2 | pan-cancer | AAC | 0.0038 | 0.9 |
| mRNA | KU 0060648 | CTRPv2 | pan-cancer | AAC | -0.0037 | 0.9 |
| mRNA | BRD-K64610608 | CTRPv2 | pan-cancer | AAC | 0.004 | 0.9 |